TransMedics Group, Inc. (NASDAQ:TMDX) Shares Purchased by Global Retirement Partners LLC

Global Retirement Partners LLC increased its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 4,132.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,259 shares of the company’s stock after buying an additional 3,182 shares during the period. Global Retirement Partners LLC’s holdings in TransMedics Group were worth $203,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Hager Investment Management Services LLC purchased a new stake in shares of TransMedics Group during the 4th quarter worth about $33,000. Sachetta LLC acquired a new position in TransMedics Group in the 4th quarter worth about $40,000. Quarry LP boosted its position in TransMedics Group by 557.1% during the third quarter. Quarry LP now owns 368 shares of the company’s stock worth $58,000 after purchasing an additional 312 shares in the last quarter. National Bank of Canada FI grew its holdings in TransMedics Group by 174.7% in the third quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after purchasing an additional 262 shares during the period. Finally, Farther Finance Advisors LLC grew its holdings in TransMedics Group by 187.0% in the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock valued at $76,000 after purchasing an additional 316 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Price Performance

TMDX stock opened at $73.00 on Wednesday. TransMedics Group, Inc. has a 1 year low of $55.00 and a 1 year high of $177.37. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The firm has a market capitalization of $2.45 billion, a PE ratio of 77.66 and a beta of 2.12. The business has a 50 day simple moving average of $67.03 and a 200-day simple moving average of $102.64.

Insiders Place Their Bets

In other news, insider Tamer I. Khayal sold 1,084 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $86.40, for a total transaction of $93,657.60. Following the transaction, the insider now owns 20,843 shares of the company’s stock, valued at approximately $1,800,835.20. The trade was a 4.94 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 7.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on TMDX. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a research report on Wednesday, February 5th. Robert W. Baird cut their target price on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Oppenheimer restated an “outperform” rating and set a $125.00 price target on shares of TransMedics Group in a research report on Tuesday, December 3rd. TD Cowen decreased their price target on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. Finally, Canaccord Genuity Group cut their price objective on TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research note on Wednesday, November 20th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $122.70.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.